The newsletter from the central resource for the Swiss biotech industry
July 2024
Swiss philanthropic foundation Botnar
Research institute with focus on immune engineering in Basel
A new independent research institute, the Botnar Institute of Immune Engineering (BIIE) was launched in Basel on June 18. The Botnar Institute of Immune Engineering (BIIE) is a newly founded non-profit research organization focused on developing computational tools and immune-based translational solutions for the diagnosis, treatment and prevention of disease. Outstanding investigators from around the globe will be recruited to its facility in Basel, Switzerland, to form a new hub of innovation in immune engineering. The BIIE is made possible by the generous endowment of over 1 billion USD from Fondation Botnar, a Swiss philanthropic foundation working to improve the health and well-being of young people around the world.
Major transactions, funding, mergers and acquisitions
First quarter highlights in the Swiss biotech industry at a glance
The beginning of 2024 has brought exciting new biotech deals, setting the stage for a promising Q2 ahead. According to e.g. PWC's projections, the biopharma industry is poised for a surge in M&A activity this year, with the potential total deal value expected to reach nearly doubling last year's numbers of USD 128.8 billion. Below info graph summarizes a selection of highlights in the Swiss biotech industry of this year's first quarter. For more info, just click on the info graph.
Horizon Europe
Extended access for researchers in Switzerland
The EU has decided that researchers in Switzerland will be eligible to participate in the first three European Research Council calls for proposals for the 2025 programme year.
This important step strengthens both Switzerland and Europe as centres of research and innovation. More...
Excerpts from the Swiss Biotech Report
Global hub for biotech innovation and collaboration
Find more articles on the importance of international collaboration for an effective global healthcare system in the Swiss Biotech Report 2024.
Congratulations!
W.A. de Vigier Foundation awards
Tandem Therapeutics, a member of the Swiss Biotech Association, won one of the prestigous awards. The W.A. de Vigier Foundation invigorates business development and provides direct financial support to young people with innovative business ideas wishing to build performance and growth oriented businesses in Switzerland.
20 years of supporting startups
Sailing the waves of innovation
Venturelab set sail in 2004, and has been designing and operating flagship startup programs to support the best entrepreneurial talents in Switzerland, including Venture Kick, Venture Leaders, the TOP 100 Swiss Startup Award, and Innosuisse Start-up Trainings. Together with successful founders, top academic collaborators, and leading industry partners, they support the best startups on their way to success. You can still vote for the startup you believe deserves to win their TOP 100 Swiss Startup Award.
Selected upcoming events & discounts for our members
BIO convention Stockholm
Be part of our Swiss Biotech Pavilion
Register now to save your spot at the BIO Europe in Stockholm from November 4-6. Use the Swiss Biotech Pavilion as your home base for your activities. The official Swiss presence is organized by Switzerland Global Enterprise in close collaboration with the Swiss Biotech Association.
Hear about exciting science and technologies in the biointerfaces community, from Swiss and international research teams in academia, hospitals and industry.
Supports the business development of pharma, biotech, medtech and digital health companies, and hosts over 1,000 representatives from leading life science companies and investors.
The meeting place for the chemical and life science industry in French-speaking Switzerland under the motto “Inspiring the Future of Chemistry and Life Sciences”.
Brings together innovators, entrepreneurs, corporate executives, venture funds, and academic researchers to explore the crucial role of partnerships in scaling and innovating businesses.
features more than 7 hours of high-level speeches and panel discussions, and a global company showcase of 25+ presentations by established public, private, emerging and seed companies.
The global biopharma industry event addresses the main challenges in investment for 2024 as well as partnering and alliance management and prospects for 2025.
The Swiss Biotech Association partners with several organizations to provide a perfect mix of education and long-term professional development with discount for our members.
The CAS course offers a comprehensive look into the world of digital healthcare, and prepares for the technical, legal, cultural and organizational challenges of digital change.
Discover exact solutions to targeted biotech startup inquiries. Enhance your strategies and solidify your knowledge, while gearing up for an engaging investor pitch.
You are receiving this email because you were in contact with us or have subscribed to our newsletter. You can unsubscribe any time, but be aware that you will not receive any more info from us.
